Glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed based on GLP-1, represent a novel class of glucose-lowering drugs that have demonstrated notable advantages in overweight or obese patients with T2DM (Gourdy et al., 2023). The gene discussed is GCG; the disease is type 2 diabetes mellitus.